The
U.K. Review on Antimicrobial Resistance (Review) has this week released a
report that highlights the extreme global health threat of antimicrobial
resistance (AMR). The Review, led by economist Jim O’Neill, specifically notes
the threat of multidrug-resistant tuberculosis (MDR-TB) and the imperative of
increased global investment in research and development to save the millions of
lives lost each year due to AMR related to tuberculosis (TB) and other
infectious diseases.
The
final report warns that if new therapies, diagnostics and a new vaccine are not
introduced, MDR-TB will be responsible for 2.5 million deaths per year by 2050,
or roughly one quarter of the forecasted 10 million deaths related to AMR –
equating to one death due to MDR-TB every 12 seconds. An interim paper entitled
Vaccines and Alternative Approaches: Reducing our Dependence on
Antimicobials, published by the Review in February 2016, also emphasized
the overwhelming need for new TB vaccines as an essential component of the
global strategy to overcome TB and to address MDR-TB.
A
key finding of the final report is that increased public and private investment
in research and development will be essential to combatting AMR – saving
millions of lives, as well as avoiding the serious economic impact of this
global public health emergency.
“The
world urgently needs new, effective TB vaccines”, said Aeras and partners who
are dedicated to achieving this goal – aiding the fight against both AMR and
the global TB epidemic. “We urge that any investment of resources to combat AMR
include the support for critical TB vaccine research and development. Together,
we can help eliminate the threat of TB,” added Aeras.
No comments:
Post a Comment